Antiarrhythmic drugs for atrial fibrillation in the outpatient setting

被引:0
作者
Tseng, Andrew S. [1 ]
Desimone, Christopher V. [1 ]
Kowlgi, Gurukripa N. [1 ]
机构
[1] Mayo Clin, Dept Cardiovas Med, Rochester, MN USA
关键词
Atrial fibrillation; Cardiac arrhythmias; Outpatients; DIRECT ORAL ANTICOAGULANTS; HEART-FAILURE; DIGOXIN; DRONEDARONE; CAFFEINE; RISK; METAANALYSIS; ASSOCIATION; ARRHYTHMIAS; DOFETILIDE;
D O I
10.23736/S0026-4806.23.08524-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With burgeoning evidence for early rhythm control in patients with atrial fibrillation (AF), the management of AF in the outpatient setting has become more challenging. The primary care clinician often serves as the frontline in the pharmacologic management of AF. Because of drug interactions and the risk of proarrhythmia, many clinicians remain hesitant about the initiation and chronic management of antiarrhythmic drug prescriptions. However, with the likely increased use of antiarrhythmics for early rhythm control, understanding and familiarity with these medications have likewise become more important, especially since patients with AF probably have other non-cardiac medical conditions that can impact their antiarrhythmic therapy. In this comprehensive review, we provide informative, high-yield cases and edifying references that will help primary care providers become comfortable handling various clinical scenarios.
引用
收藏
页码:839 / 849
页数:11
相关论文
共 50 条
  • [21] Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation
    Lakdawalla, Darius
    Turakhia, Mintu P.
    Jhaveri, Mehul
    Mozaffari, Essy
    Davis, Pamela
    Bradley, Lily
    Solomon, Matthew D.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2013, 2 (03) : 301 - 312
  • [22] Is Catheter Ablation Better Than Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation?
    Natarajan, Balaji
    Nayak, Srishti
    Pai, Ramdas G.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 131 - 140
  • [23] Atrial fibrillation. New anticoagulants and antiarrhythmic drugs
    Kaya, E.
    Frommeyer, G.
    Moennig, G.
    Eckardt, L.
    HERZ, 2012, 37 (02) : 159 - 163
  • [24] Adverse effects of antiarrhythmic drugs in patients with atrial fibrillation in Primary Care
    Benito, Luisa
    Hoyo, Jordi
    Montroig, Angels
    Fornes, Berta
    Fluxa, Guillem
    Marti, David
    Pedros, Montserrat
    Siso, Antoni
    Mont, Lluis
    Miro, Oscar
    Coll-Vinent, Blanca
    MEDICINA CLINICA, 2011, 137 (06): : 241 - 246
  • [25] Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future
    Heijman, Jordi
    Hohnloser, Stefan H.
    Camm, A. John
    EUROPACE, 2021, 23 : 14 - 22
  • [26] Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil
    Krishnamoorthy, Suresh
    Lip, Gregory Y. H.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) : 1191 - 1196
  • [27] Non-Antiarrhythmic Drugs to Prevent Atrial Fibrillation
    Concepción Moro
    Antonio Hernández-Madrid
    Roberto Matía
    American Journal of Cardiovascular Drugs, 2010, 10 : 165 - 173
  • [28] Antiarrhythmic Drug Initiation for Atrial Fibrillation in the USA: How and Where
    Newman, Joshua
    Strickberger, Adam
    Spears, Jenna
    Kowey, Peter
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2025,
  • [29] Ablation of atrial fibrillation in an ambulatory outpatient setting
    Willcox, Mark E.
    Baker, Inara
    Sedwick III, Jack
    Cerveny, Matthew
    Compton, Steven J.
    HEART RHYTHM O2, 2023, 4 (08): : 478 - 482
  • [30] Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes
    Bunch, T. Jared
    Gersh, Bernard J.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 (05) : 531 - 537